China's pharmaceutical industry will keep a steady growth in 2005, with the growth rate being a little higher than that in 2004. The reshuffle of pharmaceutical product structure will be accelerated, and China's hospital market and retailing market will remain active. The prices of pharmaceuticals in China will decline on a steady basis. On condition that the existing financial and monetary policies do not undergo big changes, the output of China's pharmaceutical industry is projected to reach 528.1 billion yuan in 2005, compared with 387.65 billion yuan in 2003 and 331.64 billion yuan for Jan.-Sep., 2004. The 2005 growth rate will be 17.46%, compared with 15.8% for 2003 and 19.86% for Jan.-Sep., 2004. The output of pharmaceutical industry of 2004 is projected to reach 449.6 billion yuan. Total sales of pharmaceuticals were 149.5 billon yuan in 2003, and the figure is projected to be 172.7 billion yuan for whole year 2004, and 196.1 billion yuan for 2005, up 15.52% and 13.55% respectively. China's medical expenses were 249.3 billion yuan in 2003, and are expected to reach 289.2 billion yuan for whole year 2004.
E-newsletter feature articles:
Western manufacturers are sourcing from China.: Major players in the manufacture of active pharmaceutical ingredients have successfully included China in their sourcing strategies, and a number of other companies have emerged specifically to ease the transaction. They say that quality and reliability have improved significantly, and costs are still among the best in the world... More
Why Hong Kong still has an edge as a trading center! : For more than a century and a half, Hong Kong has served as the gateway to Mainland China. There is nowhere better than Hong Kong for small and medium size enterprises to obtain the expertise, information and facilities needed to orientate themselves in the immense Mainland Chinese market especially as it readies itself for even greater expansion following China's entry into the WTO... More
The present status and development trend of vitamin industry in China.: The drastic price decrease of vitamins has led to the elimination of producers with no cost advantage. Producers able to self-supply intermediates and having the resulting cost advantages have, however, expanded rapidly. They have not only occupied the domestic market but also gained a firm foothold in the international market in spite of fierce competition... More
The Predicament of Compulsory GMP Certification.: The unforeseen predicament of post GMP certification is causing many Chinese pharmaceutical factories to suspend their production lines. Factories which mainly produce the common generic medicines with a low profit margin, are concurrently facing inflation on production cost and the shortage of floating capital after the GMP certification... More
Read the current issue! [www.welexchem.blogspot.com]
E-mail
Copyright © 1998 Welex Chemicals Ltd., Updated 2005. All right reserved worldwide
[